iiinova — where your digital self keeps evolving

Vadim Koshkin, MD

@vadimkoshkin.bsky.social

159 followers 108 following 2 posts

Associate Professor of Clinical Medicine @UCSF @ucsfcancer focusing on GU Oncology. Alum of @ClevelandClinic @umichmedicine @UChiPritzker Post re GU oncology

Posts Replies Media

Reposted by Vadim Koshkin, MD

Nima Sharifi MD @nimasharifimd.bsky.social · 23/02/2025

About $74 million in US govt funding (including NIH) went into developing enzalutamide - a multibillion dollar drug that prolonged life for countless men with prostate cancer. Why would anyone cut this support? We need more, not less! @ascocancer.bsky.social @theaacr.bsky.social

1126

Reposted by Vadim Koshkin, MD

Elizabeth Plimack MD @erplimackmd.bsky.social · 15/02/2025

Comparison of Adjuvant regimens for cancer across tumor types #GU25. Nivolumab per Checkmate 274 for #bladdercancer rises to the top. docs.google.com/presentation...

083

Vadim Koshkin, MD @vadimkoshkin.bsky.social · 04/02/2025

First post on this platform highlighting an important article. Pembro rechallenge for mUC pts published in @euplatinum.bsky.social Pts with response on Pembro stop Rx👉PD👉resume Pembro Rechallenge works: ORR: 41% mOS: 26 mos 👇 Pembrolizumab Retreatment in mUC www.sciencedirect.com/science/arti...

sciencedirect.com

Pembrolizumab Retreatment in Patients with Advanced or Metastatic Urothelial Carcinoma Who Responded to First-course Pembrolizumab-based Therapy

Patients with metastatic solid tumors who previously had stable disease or a response with immunotherapy may derive benefit from immunotherapy retreat…

040